Efficacy of Neoadjuvant Chemotherapy Combined with Anti-PD-1 Immunotherapy in Resectable Non-Small Cell Lung Cancer: A Prospective Phase II Trial

• • Major pathological response (MPR) rate of 60% (18/30) in resectable stage IIIA NSCLC, significantly higher than historical chemotherapy alone (15-20%), indicating enhanced tumor regression. • • Pathological complete response (pCR) rate of 33.3% (10/30), a key surrogate for long-term survival, suggesting potential for improved disease-free survival. • • Overall response rate (ORR) of 70% (21/30) by RECIST 1.1, demonstrating rapid tumor shrinkage and high clinical activity. • • Grade ≥3 treatment-related adverse events occurred in 20% of patients, with no treatment-related deaths, indicating a manageable safety profile suitable for perioperative use.